

CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (10 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
Tirzepatide is a first-in-class medication that functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This sophisticated mechanism allows for enhanced insulin secretion, suppressed glucagon release, slowed gastric emptying, and reduced appetite—all contributing to improved metabolic function and body composition.
According to research published by the National Institutes of Health, Tirzepatide has demonstrated significant efficacy in clinical trials for weight management and glycemic control, making it particularly valuable for athletes during cutting phases or those seeking metabolic optimization.
For the dedicated athlete or bodybuilder, Tirze-Pep offers several distinct advantages:
Many athletes find that incorporating Tirze-Pep into their regimen helps them achieve unprecedented definition while maintaining energy for intense training sessions. Unlike many cutting agents, Tirzepatide doesn't cause jitters or energy crashes, making it suitable for athletes who need to perform at their peak.
Every vial of Tirze-Pep undergoes rigorous third-party testing to ensure purity, potency, and sterility. Dragon Pharma's state-of-the-art manufacturing facilities comply with international quality standards, guaranteeing that each batch meets precise specifications for optimal results.
For those interested in complementary products that support metabolic health, consider our GLP-1 peptide range which offers additional options for metabolic optimization.
Tirze-Pep is typically administered via subcutaneous injection, with dosage titration recommended to minimize potential gastrointestinal side effects. Most users begin with 2.5 mg weekly, gradually increasing to a maintenance dose of 5-15 mg per week based on tolerance and response.
For best results, users should combine Tirze-Pep with a structured nutrition plan and regular exercise regimen. Those looking to enhance their training performance might consider stacking with Cardarine for improved endurance and fat oxidation.
Tirze-Pep can be effectively combined with other Dragon Pharma products for synergistic effects:
Always consult with a healthcare professional before beginning any new peptide regimen, especially when combining multiple compounds.
Tirzepatide is generally well-tolerated, with the most common side effects being transient gastrointestinal symptoms such as nausea, diarrhea, and decreased appetite—which typically diminish with continued use. Unlike many performance-enhancing compounds, Tirze-Pep does not exhibit hepatotoxicity, aromatization, or significant impacts on blood pressure.
For support in managing any potential side effects, Dragon Pharma offers ancillary products designed to optimize your experience with our peptide formulations.
Dragon Pharma has established itself as a trusted name in the performance enhancement community, with a commitment to purity, accuracy of dosing, and customer satisfaction. Our Tirze-Pep 10 mg formulation provides researchers and athletes with a reliable, high-quality source of Tirzepatide to support their metabolic and body composition goals.
Each vial contains 10 mg of pure Tirzepatide in lyophilized form, requiring reconstitution with bacteriostatic water before administration. Proper storage in a cool, dry place helps maintain stability and potency throughout the product's lifespan.
Reconstitute Tirze-Pep with bacteriostatic water, gently swirling until the powder is fully dissolved. Avoid vigorous shaking to prevent damaging the peptide structure. Typical reconstitution uses 1-2 mL of bacteriostatic water, resulting in a concentration of 5-10 mg/mL depending on your preferred dosing accuracy.
For research purposes, typical Tirze-Pep protocols begin with 2.5 mg administered once weekly via subcutaneous injection. After 4 weeks, the dose may be increased to 5 mg weekly. Further titration to 7.5 mg, 10 mg, or 15 mg weekly may be implemented based on research objectives and tolerance. Always follow appropriate research guidelines.
Unreconstituted Tirze-Pep vials should be stored refrigerated at 2-8°C (36-46°F) in their original packaging to protect from light. After reconstitution, the product remains stable for up to 56 days when refrigerated. Avoid freezing both the lyophilized powder and reconstituted solution.
Yes, Tirze-Pep can be researched alongside other metabolic enhancers such as Cardarine or SR9009 for synergistic effects. For those concerned with muscle preservation during caloric restriction, combining with selective androgen receptor modulators like Ostarine may be beneficial. Always design research protocols carefully when combining compounds.
Please log in to write TIRZE-PEP 10 MG review.
CLASSIFICATION: DUAL GIP/GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER (2 ML VIAL x 5 MG)
ACTIVE HALF-LIFE: ~ 5 DAYS
DOSAGE: 2.5–5 MG WEEKLY
ACNE: NOT REPORTED
WATER RETENTION: NOT REPORTED
HIGH BLOOD PRESSURE (HBP): POSSIBLE
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: PEPTIDE HUBS
LABORATORY TESTED: VIEW LAB RESULTS
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: KALPA PHARMACEUTICALS
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (20 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: STEALTH LABS USA
LABORATORY TESTED: VIEW LAB RESULTS
SHIPPED WITHOUT LABEL!
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS
CLASSIFICATION: RECOMBINANT HUMAN GROWTH HORMONE (rHGH)
ACTIVE SUBSTANCE: SOMATROPIN
FORM: 1 PRE-FILLED PEN x 36 IU (12 MG)
ACTIVE HALF-LIFE: ~3.5 HOURS (SUBQ)
DOSAGE: 1–4 IU/DAY FOR ANTI-AGING; 4–8 IU/DAY FOR FAT LOSS OR PERFORMANCE
WATER RETENTION: POSSIBLE (DOSE DEPENDENT)
HEPATOTOXICITY: NONE
AROMATIZATION: NO
MANUFACTURER: PFIZER
CLASSIFICATION: RECOMBINANT HUMAN GROWTH HORMONE (r-hGH)
ACTIVE SUBSTANCE: SOMATROPIN (R-HGH)
FORM: 1 CARTRIDGE x 15 MG
ACTIVE HALF-LIFE: ~2–3 HOURS
DOSAGE: MEN 4-10 IU/DAY
ACNE: POSSIBLE
WATER RETENTION: POSSIBLE
HIGH BLOOD PRESSURE (HBP): MAY INCREASE VIA FLUID RETENTION
HEPATOTOXICITY: NONE TYPICAL
AROMATIZATION: NONE
MANUFACTURER: NOVO NORDISK
CLASSIFICATION: GONADOTROPIN (LH RECEPTOR AGONIST)
ACTIVE SUBSTANCE: HUMAN CHORIONIC GONADOTROPIN
FORM: 1 LYOPHILIZED VIAL x 5000 IU + PROVIDED SOLVENT
ACTIVE HALF-LIFE: ~24–36 HOURS
DOSAGE: MEN 500-1000 IU
ACNE: POSSIBLE
WATER RETENTION: POSSIBLE
HIGH BLOOD PRESSURE (HBP): MONITOR IF AT CV RISK
HEPATOTOXICITY: NONE TYPICAL
AROMATIZATION: INDIRECT
MANUFACTURER: IBSA
CLASSIFICATION: PEPTIDE HORMONE / HCG
ACTIVE SUBSTANCE: HUMAN CHORIONIC GONADOTROPIN
FORM: 1 ML AMP x 5000 IU
ACTIVE HALF-LIFE: ~3–6 DAYS
DOSAGE: 250–1000 IU 2–3x/WEEK (ON-CYCLE or PCT)
ACNE: POSSIBLE
WATER RETENTION: MODERATE
HIGH BLOOD PRESSURE (HBP): UNLIKELY
HEPATOTOXICITY: NONE
AROMATIZATION: INDIRECTLY ELEVATES ESTROGEN
MANUFACTURER: SUN PHARMA